Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected mice

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6284-6290

  Weinstein, E A ^a   Liu, L ^b   Ordonez, A A ^a   Wang, H ^b   Hooker, J M ^c   Tonge, P J ^b   Jain, S K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 FLUORINE 18 FLUOROISONICOTINIC ACID HYDRAZIDE; ISONIAZID; ISONIAZID DERIVATIVE; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG SYNTHESIS; FEMALE; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VEIN CATHETERIZATION;

EID: 84869232183     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01644-12     Document Type: Article

References (43)

1. Almeida D, et al. 2009. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 53:4178-4184.
2. Amartey JK, Al-Jammaz I, Al-Otaibi B, Esguerra C. 2002. Novel synthesis of 2-[18F]-fluoroisonicotinic acid hydrazide and initial biological evaluation. Nucl. Med. Biol. 29:817-823.
3. Banerjee A, et al. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-230.
4. Barre J, Didey F, Delion F, Tillement JP. 1988. Problems in therapeutic drug monitoring: free drug level monitoring. Ther. Drug Monit. 10:133-143.
5. Bass JB, Jr, et al. 1994. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am. J. Respir. Crit. Care Med. 149:1359-1374.
6. Bernstein J, Lott WA, Steinberg BA, Yale HL. 1952. Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds. Am. Rev. Tuberc. 65:357-364.
7. Davis SL, et al. 2009. Bacterial thymidine kinase as a noninvasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS One 4:e6297. doi:10.1371/journal.pone.0006297.
8. Davis SL, et al. 2009. Noninvasive pulmonary [18F]-2-fluoro-deoxy-D- glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob. Agents Chemother. 53:4879-4884.
9. Dickinson JM, Aber VR, Mitchison DA. 1977. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 116:627-635.
10. Dye C, Williams BG. 2008. Eliminating human tuberculosis in the twenty-first century. J. R. Soc. Interface 5:653-662.
11. Eide FF, Gean AD, So YT. 1993. Clinical and radiographic findings in disseminated tuberculosis of the brain. Neurology 43:1427-1429.
12. Fischman AJ, Alpert NM, Babich JW, Rubin RH. 1997. The role of positron emission tomography in pharmacokinetic analysis. Drug Metab. Rev. 29:923-956.
13. Harper J, et al. 2012. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J. Infect. Dis. 205:595-602.
14. Heysell SK, Moore JL, Keller SJ, Houpt ER. 2010. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, U. S. A. Emerg. Infect. Dis. 16:1546-1553.
15. Hooker JM. 2010. Modular strategies for PET imaging agents. Curr. Opin. Chem. Biol. 14:105-111.
16. Jenne JW, Beggs WH. 1973. Correlation of in vitro and in vivo kinetics with clinical use of isoniazid, ethambutol, and rifampin. Am. Rev. Respir. Dis. 107:1013-1021.
17. Langer O, Muller M. 2004. Methods to assess tissue-specific distribution and metabolism of drugs. Curr. Drug Metab. 5:463-481.
18. Li Z, Kelley C, Collins F, Rouse D, Morris S. 1998. Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs. J. Infect. Dis. 177:1030-1035.
19. Lillebaek T, et al. 2002. Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J. Infect. Dis. 185:401-404.
20. Liu L, et al. 2010. Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons. J. Med. Chem. 53:2882-2891.
21. Lopez B, et al. 2003. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin. Exp. Immunol. 133:30-37.
22. Lu H, Tonge PJ. 2010. Drug-target residence time: critical information for lead optimization. Curr. Opin. Chem. Biol. 14:467-474.
23. Luckner SR, Liu N, am Ende CW, Tonge PJ, Kisker C. 2010. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis. J. Biol. Chem. 285:14330-14337.
24. McKenzie C. 2011. Antibiotic dosing in critical illness. J. Antimicrob. Chemother. 66(Suppl. 2):ii25-ii31.
25. Miller PW, Long NJ, Vilar R, Gee AD. 2008. Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Angew. Chem. Int. Ed. Engl. 47:8998-9033.
26. Muller M, dela Pena A, Derendorf H. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob. Agents Chemother. 48:1441-1453.
27. Musser JM, et al. 1996. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J. Infect. Dis. 173:196-202.
28. Pan H, et al. 2005. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434:767-772.
29. Parikh S, Moynihan DP, Xiao G, Tonge PJ. 1999. Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis. Biochemistry 38:13623-13634.
30. Parkin DP, et al. 1997. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 155:1717-1722.
31. Pasipanodya JG, Srivastava S, Gumbo T. 2012. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin. Infect. Dis. 55:169-177.
32. Prideaux B, et al. 2011. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal. Chem. 83:2112-2118.
33. Rawat R, Whitty A, Tonge PJ. 2003. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc. Natl. Acad. Sci. U. S. A. 100:13881-13886.
34. Rouse DA, DeVito JA, Li Z, Byer H, Morris SL. 1996. Site-directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase-peroxidase activities and isoniazid resistance. Mol. Microbiol. 22:583-592.
35. Sato T, et al. 2009. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1, 2,4-triazole, FYX-051, a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia. Bioorg. Med. Chem. Lett. 19:6225- 6229.
36. Schaaf HS, et al. 2005. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch. Dis. Child. 90:614-618.
37. Schmidt S, Banks R, Kumar V, Rand KH, Derendorf H. 2008. Clinical microdialysis in skin and soft tissues: an update. J. Clin. Pharmacol. 48:351-364.
38. Signore A, Glaudemans AW. 2011. The molecular imaging approach to image infections and inflammation by nuclear medicine techniques. Ann. Nucl. Med. 25:681-700.
39. Timmins GS, Deretic V. 2006. Mechanisms of action of isoniazid. Mol. Microbiol. 62:1220-1227.
40. Weber WW, Hein DW. 1979. Clinical pharmacokinetics of isoniazid. Clin. Pharmacokinet. 4:401-422.
41. World Health Organization. 2011. Global tuberculosis control 2011. World Health Organization, Geneva, Switzerland.
42. Zhang Y, Heym B, Allen B, Young D, Cole S. 1992. The catalaseperoxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358:591-593.
43. Zhao X, et al. 2006. Hydrogen peroxide-mediated isoniazid activation catalyzed by Mycobacterium tuberculosis catalase-peroxidase (KatG) and its S315T mutant. Biochemistry 45:4131-4140.